AstraZeneca: Lymphoma, B-Cell trials

The registry lists 15 Lymphoma, B-Cell studies with AstraZeneca as lead sponsor. 7 are open to participants now and 2 have results posted.

Phase 1 8Phase 2 5Phase 3 3No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5Not yet recruitingNCT07911553Phase 3
• A Study to Evaluate Treatment Patterns and Investigate Adult Patients With B-cell LymphomaNot yet recruitingNCT07882576
• AZD0486 1L Therapy for Elderly or Unfit Participants With LBCLRecruitingNCT07215585Phase 3
• A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT07123454Phase 1/2
• A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA RegionRecruitingNCT07065344
• A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell MalignanciesRecruitingNCT06564038Phase 1/2
• Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHLRecruitingNCT06526793Phase 2
• Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedNCT05008055Phase 2Results posted
• Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHLCompletedNCT01994382Phase 1/2Results posted
• A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT04594642Phase 1
• A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)Active, not recruitingNCT04529772Phase 3
• Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesCompletedNCT03263637Phase 1
• AZD6738 First Time in Patient Multiple Ascending Dose StudyCompletedNCT01955668Phase 1
• A Phase I Study to Evaluate Safety, Tolerability in Adults With LymphomaWithdrawnNCT00538096Phase 1
• Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877TerminatedNCT00471367Phase 1